Search the web
Welcome, Guest
[Sign Out, My Account]
Hoovers

Monday, November 9 2009 8:36am ET - U.S. Markets open in 54 minutes.
Industry Center - Biotechnology
Industry Center > Biotechnology > Amylin Pharmaceuticals, Inc. Company Profile
More On This Industry
· Summary
· News
· Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Need more? Get unbiased, in-depth information on public and private companies worldwide.
  
Amylin Pharmaceuticals, Inc. Company Profile
Amylin Pharmaceuticals helps diabetics gain the upper hand in their battle with the disease. The company makes and markets two injectable diabetes drugs, Byetta and Symlin, that are approved as adjunct therapies to other diabetes treatments such as metformin and insulin. Development partner Eli Lilly markets Byetta worldwide and is responsible for the development of Byetta in international markets. Amylin's US-based sales force co-promotes Byetta with Eli Lilly and markets Symlin on its own. The company is working on other diabetes drugs, including a once-weekly version of Byetta, as well as treatments for obesity.
Headlines for Amylin Pharmaceuticals, Inc.
AMYLIN PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
EDGAR Online - Thu Nov 5
Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
PR Newswire - Thu Nov 5
[external] Amylin To Live Large On The Fat Of The Land
at Forbes.com - Thu Nov 5
[external] Roll up for Japan's medical mystery tour
at FT.com - Wed Nov 4
More Headlines...
More on Amylin Pharmaceuticals, Inc.
Quote SEC
Chart Msgs
News Insider
Profile Financials
Reports Analyst Ratings
Research    
Contact Information
Address: 9360 Towne Centre Dr.
San Diego, CA 92121
Phone:858-552-2200
Fax:858-552-2212
Financial Highlights
Fiscal Year End:December
Revenue (2008):840.10 M
Revenue Growth (1 yr):7.60%
Employees (2007):1,900
Employee Growth (1 yr):22.60%
Key People
Chairman: Paulo F. Costa
President, CEO, and Director: Daniel M. (Dan) Bradbury
SVP Finance and CFO: Mark G. Foletta
Industry Information
Sector: Healthcare
Industry: Biotechnology
Top Competitors
GlaxoSmithKline plc (gsk)
Merck & Co., Inc. (mrk)
Novo Nordisk A/S (nvo)
 


Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2009 Morningstar, Inc. All Rights Reserved. Company information © 2009 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2009, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo! nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo! site, a user agrees not to redistribute the information found therein.

Questions or Comments?